|Bid||5.15 x 800|
|Ask||5.30 x 800|
|Day's Range||5.11 - 5.27|
|52 Week Range||3.55 - 9.25|
|Beta (3Y Monthly)||-0.31|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||14.00|
JERUSALEM, May 20, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the European Patent Office has granted the Company European Patent No. 2997953 titled, "DELIVERY DEVICE FOR ORAL INTAKE OF AN AGENT," and covers Intec's gastro-retentive drug delivery device with perforated external film. "This new patent builds on our expanding global intellectual property estate to protect our Accordion Pill® (AP) technology and its variety of applications. Importantly, the new patent underscores Intec's continued innovation with respect to the Accordion platform technology and our commitment to expanding our patent protection to safeguard the AP platform for our biopharmaceutical products and products in development. This patent specifically protects our product development efforts for poorly soluble compounds, which utilize our perforated films as part of the innovative approach to enhanced drug delivery" said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma.
"We are very excited to collaborate with Merck," said Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma. "We believe this program, as well as our ongoing collaboration with Novartis, paves the way for other new collaborations to further validate the AP platform and confirms our technical abilities to build custom APs. Importantly, these new programs offer the opportunity to pursue novel additions to our product and intellectual property portfolio," concluded Mr. Meckler.
JERUSALEM , May 7, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the three months ended March 31, 2019 and provides ...
The cannabis industry has grown in recent months and years, and many companies in the cannabis and health-related industries have been uplisted to reputable U.S. exchanges. Learn about the marijuana stocks on the Nasdaq.
JERUSALEM , May 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that the results from a pharmacokinetics (PK) study of the Accordion ...
Company on track to report top-line data in July/August time frame JERUSALEM , April 30, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces ...
Although Tuesday was just YOLO's third day on the market, the fund's portfolio manager Dan Ahrens already made some additions to YOLO's roster. Greenlane Holdings Inc. (NASDAQ: GNLN), the Florida-based maker of cannabis vape hardware and related accessories, commenced an initial public offering on April 17, the day before YOLO debuted.
JERUSALEM, April 1, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Company management will participate in the upcoming HC Wainwright Global Life Sciences Conference. Mr. Meckler's presentation will be webcast live and will be accessible through the Events section of Intec Pharma's website at www.intecpharma.com, where it will also be archived for a period of time.
Legal cannabis is becoming a mature industry as next-generation growers and processors have begun to create value-added and differentiated products, suggests Hilary Kramer, growth stock expert and editor of GameChangers.
JERUSALEM, March 13, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the Company's presentation time at Barclays Global Healthcare Conference has been changed as follows.
JERUSALEM , Feb. 28, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces that Company management will participate at the following upcoming ...
JERUSALEM , Feb. 27, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the Company") today announces financial results for the fourth quarter and year ended December ...
Key highlights of the past week are regulatory and pipeline developments along with research collaboration deals.
AP-CD/LD met primary endpoint of reducing plasma levodopa variability compared to standard oral CD/LD with statistical significance JERUSALEM , Feb. 19, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: ...
Cannabis News Xanthic Biopharma (OTCQB:GGBXF) is changing its corporate name to Green Growth Brands. In a press statement, the company said that its common shares will continue to trade on the Canadian Securities Exchange under the stock symbol "GGB" and on the OTCQB under the stock symbol "GGBXF". "The formal name change represents the next […] The post Cannabis Stock News Daily Roundup January 4 appeared first on Market Exclusive.
JERUSALEM, Jan. 2, 2019 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces the dosing of the first patient in a Phase 1 pharmacokinetic (PK) study of AP-THC, its proprietary Accordion Pill™ platform containing synthetic tetrahydrocannabinol (THC), one of the primary cannabinoids contained in cannabis. The Phase 1 PK study is a single-center, single-dose, randomized, open-label three-way crossover study to investigate the PK, safety and tolerability of AP-THC in up to 18 normal healthy volunteers.
How do we determine whether Intec Pharma Ltd (NASDAQ:NTEC) makes for a good investment at the moment? We analyze the sentiment of a select group of the very best investors in the world, who spend immense amounts of time and resources studying companies. They may not always be right (no one is), but data shows […]
JERUSALEM, Dec. 19, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that Jeffrey A. Meckler, Vice Chairman and Chief Executive Officer of Intec Pharma, has issued a Letter to Shareholders, the full text of which follows below. Throughout 2018, we have been focused on building our precommercial activities in preparation for Phase 3 AP-CD/LD data readout, potential regulatory filing and commercial launch. We have conducted considerable work in a number of areas key to a successful commercial launch, including manufacturing, market assessment, payor access, patient advocacy, regulatory, packaging and more. We are building a body of knowledge in support of AP-CD/LD as a new backbone Levodopa treatment for advanced PD patients. We believe the work we are doing now will be key to the development of a winning commercial strategy – whether we select to partner the product or to launch it ourselves.
JERUSALEM, Dec. 6, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NTEC) ("Intec" or "the Company") today announces that the Accordion Pill™ developed for a proprietary Novartis compound is continuing into a clinical PK study under the previously announced Feasibility and Option agreement with Novartis Pharmaceuticals. Following achievement of the required in-vitro specifications, the companies are continuing the program into a clinical PK study during the first half of 2019. The details of the therapeutic area or specific compound were not released.
NEW YORK, NY / ACCESSWIRE / December 3, 2018 / There was no news to explain the new high that Intec Pharma hit on Friday but Oragenics surged over 30% after announcing the publication of a research paper last week. Oragenics, Inc. shares closed up 33.66% on Friday with around 24.7 million shares traded. It was early last week that the company announced the publication of a research paper called "Blueprints for the rational design of therapeutic mutacin 1140 variants." The study focused on structure-activity relationships of the lantibiotic Mutacin 1140 (MU1140) that expand the “drugability” of the MU1140 pipeline.
NEW YORK, Nov. 21, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
Completed enrollment in pivotal Phase 3 ACCORDANCE trial; on track for topline data in mid-2019 JERUSALEM , Nov. 9, 2018 /PRNewswire/ -- Intec Pharma Ltd. (NASDAQ: NTEC) ("Intec" or "the ...
Israel's Intec Pharma, which is conducting a late stage trial for its long-lasting pill to treat Parkinson's disease, expects to start earning money from the programme sometime in 2019. Intec recently completed enrolling 462 patients for a Phase III trial for the pill that opens up like an accordion, with the levodopa drug remaining in the stomach for 8-12 hours, requiring fewer doses a day. "I hope next year we will be able to monetize value out of the Parkinson's programme, whether that is the sale of the company, sale of the programme or a licence partnership," said Meckler, who took over in July 2017.